The obesity drug pipeline in 2026

Obesity treatment has changed more in five years than in the previous three decades. A 2026 review in the Journal of Clinical Endocrinology and Metabolism by Aya Bassatne and Ivania Rizo of Boston University maps where that change is heading: away from single-target drugs and toward agents that act on several hormonal pathways at once, producing weight loss figures that were previously only seen after bariatric surgery^[1]. This article summarises the current landscape and what the research pipeline looks like.

The scale of the problem gives the urgency some context. The WHO estimates that 890 million adults worldwide now have obesity, a figure that has more than doubled since 1990. In 2021, excess body weight contributed to an estimated 3.7 million deaths from noncommunicable diseases^[3]. The stakes for better pharmacological options are not abstract.

What is already available

The first generation of approved GLP-1 receptor agonists (semaglutide 2.4 mg weekly, branded Wegovy) produced mean weight loss of around 14-15% in the STEP-1 trial at 68 weeks. That is a meaningful result, but Bassatne and Rizo note it sits in the lower tier of what is now achievable^[1]. Tirzepatide, a dual GIP and GLP-1 receptor agonist approved in the US under the Zepbound brand for obesity, cleared 20% mean weight loss in the SURMOUNT-1 trial at 72 weeks at the top dose. These are the current reference points against which every new agent in the pipeline is measured.

The shift these approvals represent is as conceptual as it is numerical. For most of the twentieth century, weight loss pharmacology targeted single pathways, and efficacy plateaued well below what patients needed. Dual agonism broke that ceiling. The question the 2026 pipeline is answering is how much higher it can go.

Triple agonists: retatrutide and what phase 2 data showed

Retatrutide (LY3437943) is the most discussed entrant in the next tier. It acts simultaneously on GLP-1, GIP, and glucagon receptors, adding the metabolic effects of glucagon activation to the appetite and insulin-secretion effects of the incretin axis. In a Phase 2 trial published in the New England Journal of Medicine, Jastreboff and colleagues reported 24.2% mean weight loss at 48 weeks on the 12 mg dose, with 100% of participants in that cohort achieving at least 5% reduction and 83% achieving at least 15%^[2]. The Bassatne and Rizo review cites retatrutide as producing reductions exceeding 25% in more recent data from Phase 3^[1].

A 2026 review in Clinical Pharmacology in Drug Development by Ganamurali and Sabarathinam examined retatrutide's mechanism in detail, noting that the triple-agonist profile generates benefits beyond weight loss: improvements in lipid panels, blood glucose control, and early signals on liver fat reduction in metabolic dysfunction-associated steatohepatitis (MASH)^[4]. None of this is yet available as an approved therapy. Retatrutide is investigational, with Phase 3 trials ongoing, and no regulatory submission has been publicly confirmed as of July 2026.

Amycretin and CagriSema: the other agents entering phase 3

Amycretin combines GLP-1 receptor agonism with amylin pathway activation. Amylin is a pancreatic hormone involved in satiety signalling, and its combination with GLP-1 is a different approach to multi-pathway therapy than adding glucagon. Early Phase 2 data from Novo Nordisk showed mean weight loss figures in the 22-24% range. Bassatne and Rizo include amycretin among the agents exceeding 20% weight reduction in their review^[1].

CagriSema is a fixed-dose combination of cagrilintide (a long-acting amylin analogue) with semaglutide. Like amycretin, it layers amylin agonism on top of GLP-1 activity. In Phase 3 data reported at the time of the review, CagriSema also exceeded 20% mean weight reduction. Both agents represent the same conceptual move as retatrutide: more pathways, more efficacy.

Beyond weight: what the newer data is showing

The Bassatne and Rizo review makes a point that deserves attention: the clinical story for these drugs is no longer only about the number on the scale. The evidence base now covers a range of organ-specific outcomes^[1]. These include reduced cardiovascular events, improved heart failure symptoms, decreased obstructive sleep apnea severity, slowed kidney disease progression, reduced joint pain in osteoarthritis, and improvement in MASH. Some of these benefits may be partially independent of weight loss itself, operating through the direct receptor activity of these agents.

This broadening of the evidence base is changing how clinicians are being asked to think about prescribing. The review's authors advocate for what they call a phenotype-guided, complication-centric approach: selecting therapy based on a patient's specific obesity-related complications rather than weight alone. That is a meaningful shift from treating a BMI number.

What we do not yet know

Several questions sit unanswered. Long-term safety data beyond three to five years is thin across all agents in this class, including the approved ones. Cardiovascular outcomes trials for retatrutide are running but not complete. Weight regain on discontinuation remains a consistent finding, and the question of whether these drugs are lifelong therapies is partly settled (evidence favours long-term use for sustained effect) but politically and economically unresolved in most health systems.

Equitable access is the other open question the review raises directly. The drugs that are currently approved carry monthly costs that are out of reach for most patients without insurance coverage or government reimbursement, and the gap between countries on that front is wide. Whether the next generation of agents narrows or widens that gap will depend on manufacturing costs, patent timelines, and reimbursement negotiations that are still years away.

The Bassatne and Rizo review frames the current moment plainly: "individualized therapy and attention to long-term safety, access, and equitable delivery of care" are the priorities, not simply finding the agent with the largest weight-loss headline^[1]. That framing is worth keeping in mind as Phase 3 results for retatrutide, amycretin, and CagriSema arrive over the next 12 to 24 months.

For readers tracking the retatrutide story specifically, see the retatrutide overview page. For context on the approved agents, the tirzepatide page covers the SURMOUNT trial data and per-country regulatory status.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides and drugs discussed may be classified as prescription medicines depending on your jurisdiction. Always consult a qualified healthcare professional before using any treatment. PeptideMethods.com does not sell, distribute, or facilitate the sale of any product.